Dr. Lanza is one of only five researchers and scientists to be acknowledged for his discoveries “behind the medicines making a significant impact on the pipelines of today and of the future.”
“Though his work has sometimes been attacked by political and religious establishments, Robert Lanza, M.D., forges ahead with research based on the right thing to do scientifically,” PharmaVOICE stated. “Dr. Lanza is boldly leading Advanced Cell Technology’s team of scientists toward bringing the benefits of human embryonic stem cell (hESC) technology to the tens of millions of people worldwide who are suffering from a host of degenerative diseases and other conditions,” the journal continued. “Committed to the science, Dr. Lanza believes treatments using hESCs have the potential to eventually offer not just treatments, but actual cures for Parkinson’s disease, macular degeneration, heart disease, and a whole host of other debilitating diseases…. Inspired by enlightened thinkers and human kindness, Dr. Lanza believes in the mission of advancing research, and he is looking forward to the next goal: to start human clinical trials using embryonic stem cells.”
“We are pleased that highly regarded journals such as PharmaVOICE continue to recognize the contributions and achievements of our researchers,” remarked William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. “Moreover, we are excited by the novel therapies our research may yield to treat indications that have few alternatives.”
Over the past year, Advanced Cell Technology has made significant progress in its RPE (retinal pigment epithelium) and its HG (hemangioblast) programs to treat degenerative retinal disorders and cardiovascular disease, and expects to file INDs for both programs by the end of 2008. Furthermore, the company announced last month that it had entered into a definitive merger agreement to acquire autologous adult stem cell company Mytogen, Inc. and its Myoblast Program for the treatment of heart failure. Mytogen has successfully completed Phase I clinical trials and will begin Phase II trials after the merger with ACT. Upon the transaction’s closing, Advanced Cell Technology will transition from a development stage to a clinical stage company.-Advanced Cell Technology
